An AstraZeneca heart disease trial failure has put Alnylam under pressure. It's mounting a defense of its medicines.

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. When Baby KJ was introduced to the world ...

A newly acquired Novartis drug cut signs of inflammation. The test will be whether that can improve people's heart health.

RFK Jr.'s vaccine questions in Samoa, former Stanford president rebuts fraud allegations, and more health news from Morning ...

Opposition to abortion restrictions should focus on values, not statistics, writes David N. Hackney, author of “Impossible ...

A scramble to prepare for massive federal cuts across the health care system is hitting rural states like Maine particularly ...

Roivant's autoimmune drug approval, Cytokinetics reports full data for heart condition treatment, and more biotech news ...

A personalized cancer vaccine developed by Moderna and Merck may be a triumph of immunology and cancer biology. It might also be the triumph of an algorithm.

AstraZeneca detailed the surprise failure of a closely watched heart disease trial, a study with ripple effects for a ...

Juul has received FDA clearance to sell an updated version of its e-cigarette, which includes an optional age-verification ...

Oxford researchers call shingles shot first vaccine protecting both heart and brain. Lower heart disease risk follows study ...

WASHINGTON — After Pennsylvania health authorities announced that two unvaccinated people had died from measles-associated ...